Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus CEFIZOX IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus CEFIZOX IN PLASTIC CONTAINER.
CECLOR CD vs CEFIZOX IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Binds to penicillin-binding proteins (PBPs) in bacterial cell wall, inhibiting peptidoglycan cross-linking, leading to cell lysis and death.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
1-2 g IV/IM every 8-12 hours; severe infections: up to 2 g every 6-8 hours; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
1.5-2 hours; prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Renal: ~80% unchanged; biliary/fecal: ~20%
Primarily renal (80-90% unchanged), with biliary/fecal elimination being minor (<10%)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic